These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 36792083)

  • 1. [Advances of Immunotherapy Resistance and Coping Strategies 
in Non-small Cell Lung Cancer].
    Jing Y; Zeng H; Cheng R; Tian P; Li Y
    Zhongguo Fei Ai Za Zhi; 2023 Jan; 26(1):66-77. PubMed ID: 36792083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies.
    Zhou S; Yang H
    Front Immunol; 2023; 14():1129465. PubMed ID: 37090727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 4. Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
    Attili I; Tarantino P; Passaro A; Stati V; Curigliano G; de Marinis F
    Lung Cancer; 2021 Apr; 154():151-160. PubMed ID: 33684660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
    Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
    Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of resistance to chemotherapy in non-small cell lung cancer.
    Min HY; Lee HY
    Arch Pharm Res; 2021 Feb; 44(2):146-164. PubMed ID: 33608812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer.
    Chen Y; Chen Z; Chen R; Fang C; Zhang C; Ji M; Yang X
    Future Oncol; 2022 May; 18(14):1757-1775. PubMed ID: 35232247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Strategies and Combinations to Improve Outcomes in Immunotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Corke L; Sacher A
    Curr Oncol; 2021 Dec; 29(1):38-55. PubMed ID: 35049678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer.
    Wang Y; Chen R; Wa Y; Ding S; Yang Y; Liao J; Tong L; Xiao G
    Front Immunol; 2022; 13():829451. PubMed ID: 35251014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
    Zhao Y; Cao Y; Chen Y; Wu L; Hang H; Jiang C; Zhou X
    Immunology; 2021 Nov; 164(3):507-523. PubMed ID: 34115389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer.
    Zeng H; Tong F; Bin Y; Peng L; Gao X; Xia X; Yi X; Dong X
    Front Immunol; 2022; 13():834142. PubMed ID: 35242138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges.
    Zhou S; Xie J; Huang Z; Deng L; Wu L; Yu J; Meng X
    Cancer Lett; 2021 Apr; 502():166-179. PubMed ID: 33450361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice.
    Zouein J; Haddad FG; Eid R; Kourie HR
    Immunotherapy; 2022 Feb; 14(2):155-167. PubMed ID: 34865502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer.
    Deng J; Ma X; Ni Y; Li X; Xi W; Tian M; Zhang X; Xiang M; Deng W; Song C; Wu H
    Cancer Med; 2022 Apr; 11(8):1787-1795. PubMed ID: 35150082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers.
    Russano M; La Cava G; Cortellini A; Citarella F; Galletti A; Di Fazio GR; Santo V; Brunetti L; Vendittelli A; Fioroni I; Pantano F; Tonini G; Vincenzi B
    Curr Oncol; 2023 Feb; 30(2):2366-2387. PubMed ID: 36826142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.